https://www.selleckchem.com/products/ipi-549.html
36, 95% CI 0.142-0.914, =0.03). Treatment with PPI/H2 blockers (HR 0.30, 95% CI 0.126-0.711, 0.01) or kanamycin/rifaximin (HR 0.26, 95% CI 0.075-0.929, =0.04) was significantly associated with a reduced risk of AKI development. AKI incidence was increased in patients with decreased liver function and was associated with poor survival. PPI/H2 blocker or kanamycin/rifaximin treatment may reduce the risk of AKI. AKI incidence was increased in patients with decreased liver function and was associated with poor survival. PPI/H2 blocker
Like
Comment
Share
